Concepedia

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Béné, Sonja Zweegman, Hélène Caillon, Denis Caillot,

The Lancet Oncology · 2021 · 175 citations · 20 references

DOIFull text

Open access

Concepts

References

20

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

S. Vincent Rajkumar, Meletios Α. Dimopoulos, Antonio Palumbo et al. · The Lancet Oncology · 2014 · 4.9K citations · Full text

, , +11

International uniform response criteria for multiple myeloma

Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel et al. · Leukemia · 2006 · 2.6K citations

, , +12

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel et al. · New England Journal of Medicine · 2016 · 1.5K citations · Full text

, , +17

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi et al. · New England Journal of Medicine · 2016 · 1.4K citations · Full text

, , +16

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister et al. · New England Journal of Medicine · 2012 · 1.1K citations · Full text

, , +15